Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience

INTRODUCTION: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus. MATERIAL AND METHODS: In this 12-week study, patients receiving twice-daily premixed insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Özçelik, Serhat, Çelik, Mehmet, Vural, Aşkı, Aydın, Bünyamin, Özçelik, Melike, Gozu, Hulya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811302/
https://www.ncbi.nlm.nih.gov/pubmed/33488849
http://dx.doi.org/10.5114/aoms.2020.93264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811302/
https://www.ncbi.nlm.nih.gov/pubmed/33488849
http://dx.doi.org/10.5114/aoms.2020.93264

Ejemplares similares